Get started
Author

Liliana Delgado

Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
2015 · Amita Patnaik, S. Peter Kang, et al. · Clinical Cancer Research · 807
First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
2011 · Timothy A. Yap, Li Yan, et al. · Journal of Clinical Oncology · 540
Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers
2014 · Timothy A. Yap, Li Yan, et al. · Clinical Cancer Research · 81
An Ultra-Sensitive Clinical Biomarker Assay: Quantitation of Thymus and Activation-Regulated Chemokine in Human Plasma
2014 · Xuemei Zhao, Liliana Delgado, et al. · Bioanalysis · 7
Influence of Pre-Analytical Factors on Thymus- and Activation-Regulated Chemokine Quantitation in Plasma
2015 · Xuemei Zhao, Liliana Delgado, et al. · Journal of Circulating Biomarkers · 5
PDF
Abstract #3604: A phase I single-rising dose study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of an oral akt inhibitor in healthy male volunteers
2009 · Michele Trucksis, Evan Friedman, et al. · Cancer Research · 5
Abstract 27: First dose-finding study in cancer patients (pts) of a potent, selective, allosteric AKT inhibitor MK2206 (MK), incorporating pharmacodynamic (PD) and predictive biomarkers and showing profound pathway blockade
2010 · Timothy A. Yap, Kyriakos Papadopoulos, et al. · Cancer Research · 3
Abstract B135: First-in-man, first-in-class phase I study of two schedules of MK-2206, a novel oral Akt inhibitor, in patients (pts) with advanced solid tumors, including ovarian and castration resistant prostate cancer (CRPC)
2009 · Timothy A. Yap, Kyriakos Papadopoulos, et al. · Molecular Cancer Therapeutics · 1
Works count: 8
Citation count: 1,449
H-index: 5
I10-index: 3
Year
Topic
Type